Hepatobiliary Cancers | Consensus or Controversy? Immune Checkpoint Inhibitors in the Management of Hepatobiliary Cancers — A 2024 Post-ASCO Gastrointestinal Cancers Symposium Review

Featuring perspectives from Dr Robin (Katie) Kelley and Dr Mark Yarchoan, including the following topics:  Introduction: Interdisciplinary Management of Hepatocellular Carcinoma (HCC) in the Community (General Medical Oncology) Setting — Radiology, Hepatology, Pathology Support (0:00) Potential Role of Anti-PD-1/PD-L1 Antibodies in the Care of Patients with Early- and Intermediate-Stage HCC — Dr Yarchoan (8:09) HCC Rounds (22:07) Tolerability and Other Practical Considerations with the Use of Immune Checkpoint Inhibitors for Advanced HCC and Biliary Tract Cancers (BTCs) — Dr Kelley (39:25) Faculty Survey (49:19) BTC Rounds (52:19) CME information and select publications